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Nondeceptive placebo has demonstrated its eﬃciency in clinical practice. Although the underlying mechanisms are still unclear,
nondeceptive placebo eﬀect and nondeceptive nocebo eﬀect may be mediated by expectation. To examine the extent to which
expectation inﬂuences these eﬀects, the present study compared nondeceptive placebo and nocebo eﬀects with diﬀerent ex-
pectation levels. Seventy-two healthy female participants underwent a standard conditioning procedure to establish placebo and
nocebo eﬀects. Sequentially, participants were randomized to one of the four experimental groups—baseline (BL), no expectation
intervention (NoEI), expectation increasing (EI), and expectation decreasing (ED) groups, to receive either no intervention or
interventions through diﬀerent verbal suggestions that modulated their expectation. Placebo and nocebo eﬀects were established
in all four groups after the conditioning phase. However, after disclosing the placebo and nocebo, the analgesic and the
hyperalgesic eﬀects only persisted in the EI group, when compared with the BL group. Our results provide evidence
highlighting the critical role of increased expectation in nondeceptive placebo and nocebo eﬀects. 2e ﬁnding suggests that
open-label placebo or nocebo per se might be insuﬃcient to induce strong analgesic or hyperalgesic response and sheds insights
into administrating open-label placebo and avoiding open-label nocebo in clinical practice.
1. Introduction
Placebo eﬀect is a psychobiological eﬀect that occurs fol-
lowing the administration of a placebo, that is, an inert
treatment [1]. In most studies, a sham substance or sham
equipment was administrated deceptively to induce in-
dividual’s expectation of placebo, promoting the treatments
for pain, motor disorders, anxiety, depression, and other
diseases [1–6]. Given that disclosing the placebo may reduce
the individuals’ expectation on positive treatments or in-
terventions, deceptively administrating placebo is consid-
ered as a standard approach to ensure that the positive
expectation can be established [7]. On the other hand, open-
label placebo is being paid close attention to in practice,
given its nondeceptive nature [8, 9]. It has been demon-
strated that open-label placebo accompanied with positive
verbal suggestion and/or a context of supportive patient-
practitioner relationship alters pain perception in patients
with irritable bowel syndrome (IBS) or chronic low back
pain [10, 11]. In addition, once individuals have experienced
the pain reduction after receiving a placebo, the disclosure of
the placebo would not lead to a failure of the placebo eﬀect
[12, 13].
Why placebo treatment is still eﬀective even when the
people have known that the treatment is inert? One plausible
explanation is that verbal suggestion, supportive patient-
practitioner relationship, and conditioning procedure in-
duce additional expectation on the eﬃcacy of the placebo,
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therefore mediating the eﬀect [2, 4, 14, 15]. However, the
extent to which expectation inﬂuences the nondeceptive
placebo eﬀect is still unclear. If one’s expectation underlies
the eﬃcacy of placebos, one would expect a reduction or
even an elimination of the placebo eﬀect after revealing the
nature of the placebo without increased expectation in-
tervention. In other words, an increased expectation of
open-label placebo may contribute to the placebo eﬀect,
while a decreased expectation may further reduce the eﬀect.
To test this hypothesis, in the present study, diﬀerent
expectation interventions (i.e., no expectation, increasing
expectation, and decreasing expectation) were administrated
accompanied with the disclosure of the placebo after the
participants have experienced the placebo eﬀect. In addition,
given that an administration of placebos may not be only
lead to placebo eﬀect but also result in nocebo eﬀect [16, 17],
a negative response to the treatment [4, 17, 18], the exam-
inations on how expectation interventions inﬂuence the
nocebo eﬀect were also included to provide insights into the
avoidance of the nocebo eﬀect via expectation modulation.
2. Methods
2.1. Participants. A total of 76 healthy (mean age� 20.89±
1.34 years; ranging from 18 to 24 years) volunteers were
recruited from the Southwest University, China. Only right-
handed female volunteers were recruited in the present
study to rule out the possible confounding factors of
handedness and gender [19, 20]. None reported with car-
diovascular or neurological diseases, family or personal
history of psychiatric disorders, acute or chronic pain, color
blindness, current use of any medication, or contraindica-
tions of electrical stimulation. To avoid confounding eﬀects
on pain perception, they were further instructed not to
consume products containing caﬀeine, nicotine, or alcohol
24 h before the experiment [21, 22]. Four participants who
were unable to discriminate the distinct levels of electrical
pain stimuli used in the conditioning phase were excluded
from further investigation. Upon arrival, the Chinese ver-
sions of the State-Trait Anxiety Inventory (STAI) [23] were
adopted to assess the anxiety state (STAI-S) and anxiety trait
(STAI-T), respectively, in all participants. All participants
gave their written consents and were informed of their rights
to discontinue participation at any time.2ey were informed
that the study aimed at examining the eﬀect of subliminal
electric stimulus equipment for pain modulation. 2e ex-
periment procedure was approved by the Ethics Committee
of the Southwest University and carried out in accordance
with the approved guidelines. 2is trial is registered with
ChiCTR1800014737.
2.2.Pain Induction. 2epainful stimuli were delivered to the
inner side of the left forearm through three stainless steel
concentric bipolar needle electrodes connected to a constant
current stimulator (model DS7A, Digitimer Ltd, Hertfordshire,
UK). Each electrode consisted of a needle cathode (length:
0.1mm, diameter: 0.2mm) surrounded by a cylindrical anode
(diameter: 1.4mm). All electrodes were located according to
an equilateral triangle shape on the inner side of the left
forearm, which has been proved to preferentially activate Aδ
nociceptive ﬁbers in the superﬁcial skin layers [24–27]. 2e
method of limits (an ascending series of stimuli in steps of
0.1mA were delivered starting from subtactile threshold
until pain sensation was induced) was used to identify the
stimulus intensity that would elicit individual pain expe-
rience [28]. Each stimulus (mean intensity � 1.21 ± 0.50mA
across all participants) consisted of several succeeding
constant current, square wave pulses (2 pulses for low pain,
10 pulses for moderate pain, and 20 pulses for high pain,
resp.), with 50Hz frequency. Before the formal experiment,
participants were familiarized with a series of electrical
pain stimuli.
2.3. Procedures. 2e experiment consisted of two phases:
a conditioning phase and a test phase, with a 10min break set
between the two phases. During the whole procedure,
participants wore a sham subliminal electric stimulus
equipment on the middle ﬁnger of their left hand.
Participants were sitting approximately 60 cm from a
19-inch monitor (display resolution: 1440× 900 pixels). As
shown in Figure 1, in the conditioning phase, each trial started
with a 3 s white ﬁxation cross centered on the screen with
black background. Sequentially, a solid circle (diameter:
2 cm), which was red, white, or green in color, was presented
on the screen for 1 s. All participants were told that the visual
cue in a certain color was associated with a certain eﬀect
(hyperalgesic eﬀect, no eﬀect, or analgesic eﬀect) caused by
the equipment. To rule out possible confounding eﬀect related
to color itself, half of the participants for each group were
informed that the green cue was associated with an analgesic
eﬀect of the equipment with low-frequency current, the red
cue was linked to a hyperalgesic eﬀect of the equipment with
high-frequency current, and white cue suggested a de-
activation of the equipment. 2e other half were told the
associations between the green cue and a hyperalgesic eﬀect
and between the red cue and an analgesic eﬀect. Two seconds
after the visual cue disappeared from the screen, a pain
stimulus was delivered to the left forearm at low, moderate, or
high level to ensure the analgesic and the hyperalgesic eﬀects
were established accordingly. Participants were required to
verbally rate the perceived pain intensity 2 s later on a 11-point
numeric rating scale (0� no pain at all; 10� unbearable pain)
within 6 s. 2e interval between trials varied from 8 s to 12 s.
2is phase consisted of two sessions, Conditioning 1 and
Conditioning 2, separated by a 3min interval. 2ere were 30
trials for each session, with 10 trials for each association
between the visual cue and pain stimulus. 2e sequence of
visual cues (red, white, or green) paired with diﬀerent pain
levels (deﬁned as low/moderate/high pain cues, resp.) were
counterbalanced across all participants.
For the test phase, the procedure was identical to that in
the conditioning phase, except that the intensity of pain
stimulus was set at the moderate level (i.e., the intensity
associated with the white cue in the conditioning phase) in
accordance with a previously described paradigm [29]. To
reduce the possible eﬀect of habituation/sensory adaption on
placebo/nocebo responses [30, 31], two sessions of 24 trials
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for each (rather than 30 trials) were included in the test
phase, with eight trials for each color of visual cues.
After Test 1, each participant was randomized into one of
the four diﬀerent experimental groups: baseline (BL) group
(N� 18), no expectation intervention (NoEI) group (N� 18),
expectation increasing (EI) group (N� 18), and expectation
decreasing (ED) group (N� 18) to receive diﬀerent in-
terventions as follows:
(1) Participants in the BL group were given no
intervention.
(2) Participants in the NoEI group were told that the
subliminal electric stimulus equipment had been
closed in Test 1, and the change of pain ratings re-
ﬂected their placebo and nocebo responses. In the
following Test 2, the subliminal electric stimulation
equipment would still be closed.
(3) Participants in the EI group were told the same
instruction as those in the NoEI group, except that
they were further told that previous studies indicate
that the nondeceptive placebo/nocebo can also
change the pain perception.
(4) Participants in the ED group were told the same
instruction as those in the NoEI group, except that
they were further told that previous studies indicated
that the placebo/nocebo responses would vanish
after the placebo/nocebo has been disclosed.
2.4. Statistical Analysis. To compare the characteristics
of participants in diﬀerent experimental groups, we
performed one-way analysis of variance (ANOVA) on (1)
age, (2) anxiety state (STAI-S), and (3) anxiety trait (STAI-
T) using “Group” (BL, NoEI, EI, and ED) as a between-
subject factor.
To exclude the diﬀerence of pain ratings among groups
in the conditioning phase, a two-way repeated measures
ANOVA was conducted on the pain ratings, using “Cue
type” (low, moderate, and high pain cues) as a within-subject
factor and “Group” (BL, NoEI, EI, and ED) as a between-
subject factor. To correct the violation of the assumption of
sphericity, either the Huynh–Feldt correction (when
epsilon> 0.75) or Greenhouse–Geisse correction was ap-
plied (when epsilon< 0.75) [32]. Multiple comparisons were
adjusted by using the Bonferroni correction, when necessary
(the same hereinafter).
To assess whether placebo and nocebo eﬀects were in-
duced successfully, a two-way repeated measures ANOVA
was conducted on the pain ratings for Test 1, using “Cue
type” (low, moderate, and high pain cues) as a within-subject
factor and “Group” (BL, NoEI, EI, and ED) as a between-
subject factor.
2e decrease of perceived pain intensity, an index of
the placebo eﬀect, was obtained by subtracting the ratings
paired with low pain cue from those paired with moderate
pain cue; the increase of perceived pain intensity, an index
of the nocebo eﬀect, was obtained by subtracting the
ratings paired with moderate pain cue from those paired
with high pain cue. To assess the inﬂuence of diﬀerent
interventions on placebo and nocebo eﬀects, we performed
two-way repeated measures ANOVA on the placebo eﬀect
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Figure 1: Experimental design. 2e experiment consisted of two phases: conditioning phase and test phase, separated by a 10min break. In
the conditioning phase, each trial started with a 3 s ﬁxation. Sequentially, a 1 s visual cue was displayed. All participants were told that the
visual cue in a certain color was associated with a certain eﬀect (hyperalgesic eﬀect, no eﬀect, or analgesic eﬀect) caused by the equipment.
Two seconds after the disappearance of the visual cue, an electrical stimulus was delivered to the participants. Following by a 2 s gap,
participants were asked to rate the perceived pain intensity within 6 s. 2e interval between trials varied from 8 to 12 s. Two sessions of 30
trials were included in the conditioning phase, separately by 3min blank. In the test phase, the procedure was identical to that in the
conditioning phase, except that (1) each session consisted of 24 trials and (2) all visual cues were associated with a moderate pain stimulus.
After Test 1, diﬀerent interventions were given to the four groups.
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Test 2) as a within-subject factor and “Group” as a be-
tween-subject factor.
In addition, paired-sample t tests were performed across
groups in Test 1 and Test 2, respectively, to verify the dif-
ference between the placebo eﬀect and the nocebo eﬀect.
3. Results
3.1. Participant Characteristics. Participant characteristics
for each experimental group are summarized in Table 1.
Results of one-way ANOVA indicated that participant
characteristics were not signiﬁcantly diﬀerent across
groups (age: F(3, 68) � 1.96, P � 0.13, ηp2 � 0.08; STAI-S: F
(3, 68) � 0.64, P � 0.59, ηp2 � 0.03; STAI-T: F(3, 68) � 0.03,
P � 0.99, ηp2 � 0.001), thus avoiding possible bias due to
individual diﬀerences when assessing the placebo and
nocebo eﬀects.
3.2. No Diﬀerence of Pain Ratings in the Conditioning
Phase. Two-way repeated measures ANOVA revealed that
pain ratings in the conditioning phase were signiﬁcantly
modulated by themain eﬀect of “Cue type” (F(1.65, 112.02)�
1171.98, P< 0.001, ηp2 � 0.95) but not by the main eﬀect of
“Group” (F(3, 68)� 0.23, P � 0.88, ηp2 � 0.01), and the in-
teraction of the two factors (F(6, 136)� 0.68, P � 0.66,
ηp2 � 0.006) (Table 2). 2is observation indicated that there
was no diﬀerence in pain ratings among groups in the
conditioning phase.
3.3. /e Induction of Placebo and Nocebo Eﬀects. To ensure
successful inductions of placebo and nocebo eﬀects, a two-
way repeated measures ANOVA was conducted on the pain
ratings for Test 1. A signiﬁcant main eﬀect of “Cue type” was
found (F(1.13, 76.76)� 126.23, P< 0.001, ηp2 � 0.65) with
nonsigniﬁcant interaction between “Cue type” and “Group”
(F(6, 136)� 0.15, P � 0.99, ηp2 � 0.006). As shown in Table 3,
participants reported highest pain scores when the stimuli
were presented with high pain cues and lowest pain scores
when the stimuli were presented with low pain cues (all
P< 0.001), indicating the placebo and nocebo eﬀects were
induced successfully. 2is pattern was consistent across
groups, as no signiﬁcant main eﬀect of “Group” was found
(F(3, 68)� 2.11, P � 0.11, ηp2 � 0.09).
3.4./e Inﬂuence of Expectation onNondeceptive Placebo and
Nocebo Eﬀects. A two-way repeated measures ANOVA on
the placebo eﬀect showed that a signiﬁcant main eﬀect of
“Test” (F(1, 68)� 46.74, P< 0.001, ηp2 � 0.41) and a signiﬁcant
interaction between “Test” and “Group” (F(3, 68)� 3.04,
P � 0.04, ηp2 � 0.12). As can be seen in Figure 2 and Table 4,
post hoc analyses showed that participants who underwent
no intervention (i.e., BL group) showed comparable placebo
eﬀect in Test 1 and Test 2 (P � 0.22). Participants in the
NoEI, EI, and ED groups, on the other hand, showed smaller
placebo eﬀect (but still signiﬁcant when compared with “0”
to demonstrate the existence of the placebo eﬀect; all T(17)> 2.79 and all P< 0.05) in Test 2 when compared with Test 1
(all P< 0.003). More importantly, NoEI and ED in-
terventions but not EI interventions were more likely to
reduce the placebo eﬀect established in Test 1 when com-
pared to the baseline (both P< 0.05). No other signiﬁcant
eﬀects were found.
Similar to the results of the placebo eﬀect, the analysis of
the nocebo eﬀect showed a signiﬁcant main eﬀect of “Test”
(F(1, 68)� 40.37, P< 0.001, ηp2 � 0.37), along with a signiﬁ-
cant interaction between “Test” and “Group” (F(3, 68)�
7.93, P< 0.001, ηp2 � 0.26). As can be seen in Figure 2 and
Table 4, post hoc pairwise comparisons showed that the
nocebo eﬀect was smaller for the NoEI group (but still
signiﬁcant when compared with “0” to demonstrate the
existence of the nocebo eﬀect, T(17)� 2.96, P � 0.009) and
disappeared for the ED group (not signiﬁcant when com-
pared with “0” to show the disappearance of the nocebo
eﬀect, T(17)�−0.18, P � 0.86) in Test 2 in comparison to
Test 1 (all P< 0.001). Furthermore, the nocebo eﬀect was less
aﬀected in the BL and EI groups than in the NoEI and ED
groups in Test 2 (all P< 0.05, except the P value for the
comparison between the BL and NoEI groups was 0.06). No
other signiﬁcant eﬀects were found.
3.5. /e Comparison between Placebo and Nocebo
Eﬀects. 2ere were no signiﬁcant diﬀerence between the
placebo eﬀect and nocebo eﬀect for each group in Test 1 (BL
Table 1: Characteristics of participants in each experimental group.
Group N Age STAI-S STAI-T
BL 18 21.06± 1.83 39.72± 9.43 41.72± 5.80
NoEI 18 21.00± 1.45 37.72± 8.01 42.33± 8.04
EI 18 21.50± 1.62 36.28± 3.98 42.17± 6.34
ED 18 21.28± 1.60 37.83± 7.46 42.28± 6.73
Data are expressed asmean± standard deviation.N: number of participants;
STAI-S: state subscale of State-Trait Anxiety Inventory; STAI-T: trait
subscale of State-Trait Anxiety Inventory.
Table 2: Pain ratings of each experimental group in the condi-
tioning phase.
Group
Pain ratings in conditioning phase
Low pain cue Moderate pain cue High pain cue
BL 1.18± 0.66 4.38± 1.15 7.22± 1.27
NoEI 1.10± 0.77 3.83± 0.93 7.26± 1.23
EI 1.07± 0.55 4.07± 0.93 7.23± 1.06
ED 1.17± 0.51 4.16± 0.97 7.05± 1.11
Data are expressed as mean± standard deviation.
Table 3: Pain ratings of each experimental group in Test 1.
Group
Pain ratings in Test 1
Low pain cue Moderate pain cue High pain cue
BL 4.43± 1.59 5.65± 1.36 6.86± 1.62
NoEI 3.43± 1.47 4.62± 1.29 5.77± 1.77
EI 3.48± 1.37 4.93± 1.38 6.14± 1.74
ED 3.27± 1.88 4.63± 1.75 5.92± 2.16
Data are expressed as mean± standard deviation.
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group: T(17) 0.02, P  0.99; NoEI group: T(17) 0.22,
P  0.83; EI group: T(17) 1.12, P  0.28; ED group: T(17)
0.44, P  0.67) and in Test 2 (BL group: T(17)−0.07,
P  0.95; NoEI group: T(17)−0.35, P  0.73; EI group:
T(17)−1.94, P  0.07; ED group: T(17) 1.53, P  0.14).
4. Discussion
e aim of the present study was to investigate the extent to
which expectation aects nondeceptive placebo and nocebo
eects. To this end, all participants rst underwent a con-
ditioning phase, where after associations between pain
stimuli and visual cues were established, as reected by the
placebo and nocebo eects in Test 1. Sequentially, partici-
pants were assigned to one of the four experimental groups
(i.e., BL, NoEI, EI, and ED) to receive no intervention or
dierent verbal interventions that modulated their expec-
tation of the upcoming pain stimuli in Test 2.
ree main ndings emerged in the present study. First,
when revealing that the treatment in Test 1 was a placebo, the
placebo eect persisted only in the group with increased
expectation on the placebo, when compared with the
baseline. In contrast, the placebo eect was signicantly
reduced in groups with decreased or no expectation in
compared to that in the BL group. Second, results on the
nocebo eect yielded to similar pattern, where the disclosure
of the nocebo has neither hindered nor reduced the nocebo
eect if expectation increasing intervention was introduced,
but it reduced when no expectation was administered and
disappeared when decreasing expectation intervention was
administered. ird, no dierence on eect size between
nondeceptive placebo and nocebo eects was found for all
groups.
One major nding of the present study is that non-
deceptive placebo eect only persisted when individuals
were administered with expectation increasing intervention.
is observation is partly inconsistent with previous studies
showing that nondeceptive placebo treatments could lower
participants’ disease symptoms and pain perception [10–12],
as reduced nondeceptive placebo eects were found in
groups with decreased and no expectation intervention
when compared with the baseline. It is possible because the
claim on eectiveness of nondeceptive placebo is usually
based on the manipulations that only positive verbal sug-
gestion was given to participants as open-label placebo
(e.g., Carvalho et al.’s study) or the disclosure of placebo just
happens after participants have experienced the analgesic
eect (e.g., Schafer et al.’s study), which contributes to the
placebo eect [33–35]. In other words, dierent from the
present study, the previous studies did not compare situa-
tions with increased, decreased, and/or no expectation of
placebo eect. From this perspective, our nding extends
our current understanding of nondeceptive placebo eect by
emphasizing the important role of expectation in the
process.
Indeed, it has been proved that expectation is one of the


























































Figure 2: Placebo eect (a) and nocebo eect (b) in Test 1 and Test 2. Error bars indicate one standard deviation, and data from participants
in Test 1 and Test 2 are marked in solid and hollow circles, respectively.
Table 4: Placebo and nocebo eects of each experimental group in
the test phase.
Group









BL 1.22± 1.25 1.22± 0.83 0.96± 1.02 0.98± 0.73
NoEI 1.18± 0.85 1.15± 1.02 0.33± 0.50 0.38± 0.54
EI 1.45± 1.29 1.20± 0.78 0.81± 0.77 1.08± 0.86
ED 1.36± 1.13 1.29± 0.81 0.23± 0.28 −0.02± 0.51
Data are expressed as mean± standard deviation.
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eﬀect [3, 4, 36–39]. To evaluate the relationship between
expectation and nondeceptive placebo eﬀect, we altered
participants’ expectation on the eﬀectiveness of placebo by
administrating diﬀerent verbal suggestions. Verbal sugges-
tion is widely used as an approach of expectation modu-
lation. For example, healthy individuals’ pain tolerance is
increased after receiving suggestion of analgesic placebo
given verbally [4]. Verbal suggestion can also change pa-
tients’ expectations and mediate placebo eﬀects in many
diseases [1], such as Parkinson’s disease [40], and clinical
pain [41, 42].
2e modulation of expectation can also aﬀect non-
deceptive nocebo eﬀect. For our sample, the disclosure of the
nocebo eliminated the established nocebo eﬀect for those
receiving decreased intervention and reduced the non-
deceptive nocebo eﬀect for those with no expectation in-
tervention but not for those with expectation increasing
intervention. It is possible because increased expectation of
the upcoming treatments not only leads to the placebo eﬀect
but also leads to perceived side eﬀects [4]. In other words, the
manipulation on expectation increased group made those
participants to believe that they would experience similar
placebo and nocebo eﬀects as in deceptive condition
(i.e., Test 1). 2is ﬁnding is in good agreement with a recent
study suggesting that individuals with higher-priced treat-
ment (usually leads to higher expectation) tend to exhibit
stronger nocebo eﬀect [43]. In contrast, for those partici-
pants with no or decreased expectation on the nocebo, the
disclosure of nocebo may arouse their suspicions of the
treatment, thus reducing participants’ expectation of
nocebo. In brief, compared with nondeceptive placebo eﬀect,
nondeceptive nocebo eﬀect might be more susceptible to
verbal suggestion.
Deceptive placebo and nocebo are widely administrated
in double-blinded experimental settings to evaluate the ef-
fectiveness of the target manipulation (e.g., administration
of inert substance or sham treatment) without conscious
deception [7, 44]. Typically, individuals are induced to
believe that the inert substance or sham treatment is eﬀective
[44, 45]. Although such a placebo has been widely used in
clinical practice [8, 9], giving a placebo intervention de-
ceptively as a treatment is totally unacceptable in some cases
[44, 46]. From this perspective, open-label placebos should
be used when individuals have positive expectation of the
treatment [8, 9, 47]. However, as the eﬃcacy of the placebo
may decrease after disclosure, how to maintain or improve
the eﬀectiveness of placebos without deception in various
clinical situations needs to be further studied.
In addition, side eﬀects caused by nondeceptive placebo
and nocebo should be taken into consideration seriously in
clinical practice. As previous ﬁndings suggested, individuals
with increased expectation of the treatment may also show
increased nocebo eﬀect [16, 43, 48]. 2erefore, when dis-
closing of pharmacological properties of the drug and
possible side eﬀect in the informed consent, there is a risk
that it may cause patient’s suspicion of the drug eﬀective-
ness, resulting in negative response to the treatment
[17, 49, 50]. To avoid it, suﬃcient and rational explanation of
the potential side eﬀects is needed.
5. Conclusion
2e present study provides experimental evidence showing
that deception is not necessary to achieve a placebo response
[9]. Open-label placebo with positive verbal intervention
(i.e., increased expectation) can also alter one’s pain per-
ception. In addition, to our knowledge, it is the ﬁrst study
to demonstrate that the modulation of expectation can
also aﬀect nondeceptive nocebo eﬀect, which provides an
alternative way to avoid side eﬀects of placebo treatment or
medical therapy. Overall, our study demonstrated that ex-
pectation plays a vital role in nondeceptive placebo and
nocebo eﬀects, which calls for future studies focusing on
translating the present experimental ﬁndings into clinical
practice settings.
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